Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MG-K10 (a Humanized Monoclonal Antibody Injection) in Adolescents With Moderate-to-Severe Atopic Dermatitis

NCT07540442 is registered in ClinicalTrials.gov with Shanghai Mabgeek Biotech.Co.Ltd as lead sponsor.

NCT NCT07540442
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07540442 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MG-K10 (a Humanized Monoclonal Antibody Injection) in Adolescents With Moderate-to-Severe Atopic Dermatitis
Lead sponsor
Shanghai Mabgeek Biotech.Co.Ltd
Phase
Phase 3
Overall status
Not yet recruiting
Start date
April 17, 2026
Completion date
November 9, 2027
Enrollment
180 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis, atopic